13,206 reports of this reaction
8.4% of all METOCLOPRAMIDE reports
#1 most reported adverse reaction
TARDIVE DYSKINESIA is the #1 most commonly reported adverse reaction for METOCLOPRAMIDE, manufactured by ANI Pharmaceuticals, Inc.. There are 13,206 FDA adverse event reports linking METOCLOPRAMIDE to TARDIVE DYSKINESIA. This represents approximately 8.4% of all 156,854 adverse event reports for this drug.
Patients taking METOCLOPRAMIDE who experience tardive dyskinesia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
TARDIVE DYSKINESIA is moderately reported among METOCLOPRAMIDE users, representing a notable but not dominant share of adverse events.
In addition to tardive dyskinesia, the following adverse reactions have been reported for METOCLOPRAMIDE:
The following drugs have also been linked to tardive dyskinesia in FDA adverse event reports:
TARDIVE DYSKINESIA has been reported as an adverse event in 13,206 FDA reports for METOCLOPRAMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
TARDIVE DYSKINESIA accounts for approximately 8.4% of all adverse event reports for METOCLOPRAMIDE, making it one of the most commonly reported side effect.
If you experience tardive dyskinesia while taking METOCLOPRAMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.